Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

87 results about "Bevacizumab" patented technology

This medication is a man-made antibody (IgG1) used to treat kidney, cervical, ovarian, colon, and rectal cancer. Bevacizumab is also used to treat lung cancer (non-small cell type), certain types of brain tumors, and cancer found in the fallopian tube or lining of the abdominal wall (peritoneal).

Methods and compositions for classifying and treating kidney cancer

The invention provides methods and compositions for classifying kidney cancer (e.g., RCC, e.g., an inoperable, locally advanced, or metastatic RCC); methods and compositions for treating kidney cancer in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab) to the patient. Also provided are compositions, pharmaceutical compositions, kits, and articles of manufacture for use in classifying and treating kidney cancer in a patient.
Owner:GENENTECH INC

Marker for evaluating curative effect of TACE combined with Czodili monoclonal antibody and bevacizumab in treatment of hepatocellular carcinoma, and construction method and application of FAAP prognostic scoring model

ActiveCN121068921AMedical data miningHealth-index calculationFetuin bTumor thrombus
The invention belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of treating hepatocellular carcinoma by combining TACE with Czodili monoclonal antibody and bevacizumab, and a construction method and application of an FAAP prognostic scoring model. The invention develops and verifies an FAAP prognostic scoring system, and a novel composite model integrates four indexes of fibrin degradation product / cholinesterase ratio * 1000 (FCR), aspartate aminotransferase (AST), alpha fetoprotein (AFP) and portal vein tumor thrombus (PVTT), and is used for predicting the survival condition of uHCC patients subjected to TACE-Czodimab-bevacizumab triple therapy. The tool has an instant clinical value, can optimize patient selection, guides adaptive treatment upgrading, and provides a standardized curative effect evaluation basis for a clinical test for exploring a TACE-immunotherapy-anti-angiogenesis combined scheme.
Owner:PEOPLES HOSPITAL PEKING UNIV

Intermittent Dosing of Glucocorticoid Receptor Modulators for the Treatment of Ovarian and Other Cancers

Methods and compositions for treating cancer (e.g., ovarian, fallopian tube, uterine, cervical, vaginal, vulvar, or peritoneal cancer) are disclosed. The methods include intermittent administration of a glucocorticoid receptor modulator (GRM), such as a non-steroidal GRM (e.g., relacorilant), which may be orally administered, along with a cancer chemotherapy agent (such as, e.g., bevacizumab) to the patient. The GRM may be administered: at intervals separated by at least one day without GRM administration; by a schedule linked to the cancer chemotherapy schedule (e.g., a weekly chemotherapy regimen); the day of, or the day before, or the day after, chemotherapy administration; by combinations thereof; and / or on other days. Ovarian cancer patients receiving intermittent relacorilant administration along with nab-paclitaxel administration had improved overall survival, improved progression free survival, improved duration of response, and other benefits as compared to patients not receiving relacorilant while receiving nab-paclitaxel.
Owner:CORCEPT THERAPEUTICS INC

Method for preparing bevacizumab

The invention belongs to the field of protein purification, and relates to a method for preparing bevacizumab, which comprises the steps of affinity chromatography, virus inactivation, deep filtration, composite anion exchange chromatography, cation exchange chromatography and the like.
Owner:NANJING SHUNXIN PHARM CO LTD OF CHIATAI TIANQING PHARM GRP +1

Use of gansixiaoruwei triol A in preparation of a drug for treating gastric cancer and / or non-small cell lung cancer

PendingCN122624500AApoptosisTanshinone IIA
The present application relates to the technical field of medicine, in particular to the application of gansix triol A in the preparation of a drug for treating gastric cancer and / or non-small cell lung cancer, gansix triol A plays an anti-gastric cancer role by selectively inhibiting the proliferation of gastric cancer MGC-803 cells and inhibiting angiogenesis, the mechanism involves inhibiting the VEGF / VEGFR2 signal pathway and inducing cell apoptosis; the mechanism of gansix triol A in inhibiting the VEGF / VEGFR2 signal pathway is similar to that of bevacizumab; gansix triol A plays an anti-non-small cell lung cancer role by selectively inhibiting the proliferation of non-small cell lung cancer A549 cells, the mechanism involves inhibiting the MAPK / ERK signal pathway and inducing cell apoptosis. The present application finds that the cytotoxic activity of gansix triol A on MGC-803 cells and A549 cells is significantly stronger than that of tanshinone IIA; gansix triol A has an anti-tumor effect of "one drug with double targets, double inhibition" and "high efficiency and low toxicity".
Owner:CHINESE PEOPLES LIBERATION ARMY UNIT 32235

Application of Dehydrovomifol sensitized bevacizumab in treatment of cervical cancer

PendingCN121129817AOrganic active ingredientsAntibody ingredientsAngiogenesis InhibitionCervical ca
The invention relates to the technical field of biological medicines, and particularly discloses an application of Dehydrovomigol sensitized bevacizumab in treatment of cervical cancer. The invention further relates to a preparation method of the Dehydrovomigol sensitized bevacizumab. Compared with a bevacizumab single drug, the effect of the bevacizumab on growth and proliferation inhibition, invasion blocking and angiogenesis inhibition of cervical cancer cells can be remarkably enhanced by combining the Dehydrovomifolol, and the drug resistance of the bevacizumab is reversed. In different experimental models, the Q value of the combination scheme is greater than or equal to 1.15, and the stable synergistic anti-cervical cancer effect is shown. Dehydrovomifolol realizes the effect of enhancing the anti-cervical cancer activity of the bevacizumab by virtue of triple mechanisms of reversing drug resistance, enhancing anti-angiogenesis and regulating an immune microenvironment. According to the combination scheme, the anti-cervical cancer curative effect can be improved, the clinical medication dosage of bevacizumab is reduced, the occurrence risk of toxic and side effects such as hypertension and proteinuria is reduced, and a novel, safe and efficient treatment strategy is provided for cervical cancer treatment.
Owner:NORTHWEST UNIV

PLK1 inhibitor in combination with Anti-angiogenics for treating metastatic cancer

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
Owner:CARDIFF ONCOLOGY INC

Monoclonal antibodies recognizing bevacizumab and uses thereof

This invention provides a monoclonal antibody for recognizing bevacizumab and its applications. The antibody or antigen-binding fragment provided by this invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and light chain variable region have a) the following amino acid sequences: heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 in the heavy chain variable region as shown in SEQ ID NO:1; and light chain CDR1, light chain CDR2, and light chain CDR3 in the light chain variable region as shown in SEQ ID NO:2; or b) the following amino acid sequences: heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 in the heavy chain variable region as shown in SEQ ID NO:11; and light chain CDR1, light chain CDR2, and light chain CDR3 in the light chain variable region as shown in SEQ ID NO:12. This invention fills a gap in the industry for tools and reagents in the field of bevacizumab pharmacological evaluation.
Owner:BEIJING CHENGYI BIOTECHNOLOGY CO LTD

Methods of treating cancer and other conditions with a mu opioid receptor antagonist

Provided herein are compositions and methods of using a Mu opioid receptor (MOR) antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor (such as e.g. an inhibitor of the PD-1 / PD-L1 pathway (e.g. an antibody such e.g. pem-brolizumab)) and / or an inhibitor of VEGF (e.g. bevacizumab) for reducing angiogenesis or treating cancer. Also provided herein are kits containing a MOR antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor and / or an inhibitor of VEGF for reducing angiogenesis or treating cancer.
Owner:GLYCYX MOR INC

Nanometer embolism microsphere based on magnetocaloric effect as well as preparation method and application of nanometer embolism microsphere

The invention provides a nano embolism microsphere based on a magnetocaloric effect and a preparation method and application thereof, and relates to the field of medicines. According to the nano embolization microsphere, mesoporous ferroferric oxide is used as a carrier, and rificiguat and bevacizumab are loaded at the same time. The preparation method has the beneficial effects that the magnetic nano embolism microsphere system is constructed for the first time and is combined with the magnetocaloric effect; according to the invention, the embolism system of the magnetic nano-microsphere loaded rificiguat and bevacizumab is constructed for the first time; compared with an embolism agent for independently embolizing the blood vessel, the nano embolism microsphere disclosed by the invention also plays a role in killing residual tumor cells; compared with an uncontrollable embolism agent, the nano embolism microsphere disclosed by the invention can be used for accelerating drug release in an alternating magnetic field and a slightly acidic environment.
Owner:THE FIRST AFFILIATED HOSPITAL OF HAINAN MEDICAL UNIV

Method for detecting drug concentration of bevacizumab

The invention provides a method for detecting the drug concentration of bevacizumab. The method comprises the following steps: taking a solution containing infliximab as an internal standard working solution, and determining the drug concentration of the bevacizumab in a sample to be detected by adopting liquid chromatography-tandem mass spectrometry. In drug monitoring for clinical detection of the bevacizumab concentration in human plasma, infliximab is adopted as an internal standard, the detection requirement can be effectively met, and the detection cost is reduced. The infliximab serves as an internal standard, methodological requirements of the established method can be met, and accuracy and reliability of detection results are ensured. In addition, by optimizing the sample pretreatment process, the operation steps are simplified, the detection time is shortened, manual operation errors are reduced, and the detection accuracy and efficiency are further improved.
Owner:BEIJING TSINGHUA CHANGGUNG HOSPITAL

Application of combination of Apicidin and Bevacizumab in preparation of medicine for treating cervical cancer

The invention provides application of combination of Apicidin and Bevacizumab in preparation of a medicine for treating cervical cancer, and belongs to the technical field of anti-tumor medicines. Researches show that the Apicidin improves the sensitivity of cervical cancer cells to the targeted drug Bevacizumab, the combined use of the Apicidin and the targeted drug Bevacizumab can more effectively inhibit the growth of the cervical cancer cells, the ability of inducing the apoptosis of the cervical cancer cells is also enhanced, and the Apicidin and the targeted drug Bevacizumab have a good synergistic effect. Therefore, the application prospect of the combination of the Apicidin and the targeted drug Bevacizumab is huge, a more effective feasible scheme is provided for clinical treatment of cervical cancer, and a new theoretical basis is provided for clinical combined treatment of recurrence and drug resistance of cervical cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY +1

Use of Anti-PD-1 antibody combined with chemotherapeutic agent in treatment of tumors

Provided is a use of an anti-PD-1 antibody combined with a chemotherapeutic agent in the treatment of tumors such as cervical cancer or endometrial cancer. In some embodiments, the chemotherapeutic agent comprises a taxane drug and / or a platinum drug. In some embodiments, the use further comprises a use of the anti-PD-1 antibody combined with bevacizumab.
Owner:BIO THERA SOLUTIONS LTD

Methods for treatment of liver cancer

The present invention relates to the treatment of liver cancer, e.g., hepatocellular carcinoma (HCC), e.g., resectable HCC. More specifically, the invention pertains to the treatment of patients having an HCC by administering (i) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab); (ii) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab), a VEGF antagonist (e.g., bevacizumab), and an anti-TIGIT antagonist antibody (e.g., tiragolumab); or (iii) a combination of a bispecific antibody that binds to PD-1 and LAG3 (e.g., tobemstomig) and a VEGF antagonist (e.g., bevacizumab).
Owner:GENENTECH INC

Single-cell transcriptome-guided multi-modal synergistic injectable magnetoresponsive biomimetic hydrogel system, preparation method and application thereof

PendingCN122351468ALocal HyperthermiaSingle cell transcriptome
A single-cell transcriptome-guided multimodal synergistic injectable magnetically responsive biomimetic hydrogel system, its preparation method, and its application are described. This hydrogel platform is a three-level composite system of "matrix-microsphere-nanoparticle": the primary structure is a photocrosslinked methacryloyl hyaluronic acid three-dimensional network matrix; the secondary structure is GelMA microspheres loaded with MTPT nanoparticles prepared by microfluidic control; and the tertiary structure consists of bevacizumab and magnetite nanoparticles dispersed in the HAMA matrix. The MTPT nanoparticles have a mesoporous silica core, which is sequentially coated with temozolomide, a polydopamine coating, and a T7 targeting peptide. Under the activation of an alternating magnetic field, Fe3O4 generates a magnetothermal effect, which not only achieves local hyperthermia but also accelerates the time-sequential release of bevacizumab and MTPT, synergistically exerting the effects of chemotherapy, anti-angiogenic therapy, and hyperthermia.
Owner:OUJIANG LAB

Combined administration of irinotecan lipidosome for treating colorectal cancer

The invention relates to irinotecan liposome combined administration for treating colorectal cancer. Specifically, the invention relates to application of irinotecan lipidosome combined with oxaliplatin, 5-fluorouracil, calcium folinate and bevacizumab in preparation of medicines for treating colorectal cancer, and the irinotecan lipidosome contains hydrogenated soybean lecithin, polyethylene glycol 2000-distearoyl phosphatidyl ethanolamine and cholesterol.
Owner:JIANGSU HENGRUI MEDICINE CO LTD

Methods and compositions for treating solid tumor using f16 isoindole small molecules

To provide pharmaceutical compositions for treating solid tumor, in particular, glioblastoma multiforme (GBM).SOLUTION: Provided herein is a pharmaceutical composition for use in a method for retarding progression of brain tumor, where the composition comprises a therapeutical effective dose of F16, that is, isoindole (1, 3-dioxy-2, 3-dihydro-1H-isoindol-4-yl)-amide and a therapeutically effective dose of a chemotherapeutic agent in a pharmaceutical carrier, where the brain tumor is glioblastoma multiforme, and the chemotherapeutic agent is temozolomide (TMZ) or bevacizumab (BVZ) or similar agent.SELECTED DRAWING: Figure 1
Owner:NOVA SOUTHEASTERN UNIVERSITY

Application of glutathione in relieving toxic and side effects of bevacizumab immune system

The invention belongs to the technical field of medicines, and particularly relates to a novel method for relieving toxic and side effects of bevacizumab. Based on preclinical research, the combination of glutathione and bevacizumab relieves toxic and side effects on immune cells when bevacizumab is independently used. Experimental data comparison shows that compared with bevacizumab single drug treatment, the combined glutathione can significantly reduce the inhibition effect on immune cell activity, so that the cell proliferation activity is repaired, and meanwhile, the disordered cell cycle and the abnormally expressed cell factor level tend to be normalized. The invention provides a novel treatment scheme and thought for targeted treatment of tumor patients with the VEGF monoclonal antibody bevacizumab, is also beneficial to research on the toxic action mechanism of drugs and optimization of the treatment scheme, and has important potential clinical experimental research value.
Owner:CHANGZHOU UNIV +1

A bici scoring system for predicting the efficacy of immunotherapy combined with targeted therapy in metastatic colorectal cancer and applications thereof

PendingCN122638096AEfficacyCD8
The application discloses a BICI scoring system for predicting the curative effect of immunotherapy for metastatic colorectal cancer and application thereof, and belongs to the technical field of biological medicine. The BICI scoring system is based on immunohistochemical detection, integrates four dimensions of angiogenesis, immune checkpoints, TGF-beta signal and immune activation, and is calculated by a formula IHC-BICI=VEGFA+PD-L2+TGFB1x2-CD8 score. Taking 4 points as a cut point, BICI-High and BICI-Low are divided, and a bevacizumab combined with an immune checkpoint inhibitor treatment benefit population is accurately screened. The application also discloses a detection kit containing four specific antibodies, application thereof and a treatment decision method. The scoring system of the application only needs conventional IHC detection, has low cost, excellent prediction effect, is suitable for second-line and above treatment and clinical stratification of MSS / pMMR type metastatic colorectal cancer, and has important clinical application value.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Injection composition for treating fundus macular edema and preparation method thereof

The invention discloses an injection composition for treating fundus macular edema and a preparation method thereof, and relates to the technical field of injection compositions. The medicament specifically comprises a medicament A, a medicament B, a medicament C, a medicament D, a medicament E and a medicament F. The medicament A, the medicament B, the medicament C, the medicament D, the medicament E and the medicament F are specifically and respectively composed of trifluoromethasone, bevacizumab, vitamin E, warfarin, lirabel and macacin. The mass percent of the medicament A is 2.2 to 12.5 percent, the mass percent of the medicament B is 4.3 to 33.1 percent, the mass percent of the medicament C is 8.5 to 24.7 percent, the mass percent of the medicament D is 5.5 to 13.2 percent, the mass percent of the medicament E is 7.1 to 26.3 percent, and the mass percent of the medicament F is 6.4 to 23.8 percent. The nano filter membrane is adopted for filtration, microorganisms and particles can be effectively filtered out, and the sterility of a medicine solution is ensured; under the action of an electric field and ultrasonic waves, the motion trails of the microorganisms and the particles can be changed.
Owner:ZHAOLIANG BIOPHARMACEUTICAL (SHANGHAI) CO LTD

Method and device for predicting lifetime of CRLM patient, medium and program product

The invention provides a method, a system, equipment, a medium and a program product for predicting the lifetime of a CRLM patient, further discloses a method, a system, equipment, a medium and a program product for predicting the RAS gene mutation risk of the CRLM patient, and relates to the field of intelligent medical treatment. The vein phase image and the arterial phase image are respectively input into a classifier to calculate DL scores of different periods of a subject, the DL scores of different periods are integrated, and the function of predicting the lifetime is realized based on an integration result. Meanwhile, the RAS gene state is evaluated based on the classifier for calculating the DL score, the survival rate and the lifetime of the subject are predicted based on the RAS gene state, targeted drugs suitable for being treated are recognized, and patients most likely to benefit from cetuximab or bevacizumab treatment are recognized.
Owner:SHANGHAI CHUDONG INTELLIGENT TECH CO LTD

Ophthalmic composition of bevacizumab

To provide an ophthalmic composition of bevacizumab.SOLUTION: Provided is an ophthalmic composition of bevacizumab; a. herein, the limit of Bacterial Endotoxins Test (BET) is within the range of 0.001 to 0.4EU / mg, preferably within the range of 0.001 to 0.2Eu / mg, and more preferably within the range of 0.001 to 0.16Eu / mg; b. herein, a particulate substance is as follows; 1 to 50 particles≥diameter 10 μm per iv.ml, 0 to 5 particles≥diameter 25 μm per v.ml, and 0 to 2 particles≥diameter 50 μm per vi.ml; and c. herein, the composition has an aggregate of 0.1 to 5%, more preferably 0.1 to 4%, and most preferably 0.1 to 3.5% for 2 to 3 years, preferably for 2 to 2.5 years, and most preferably for 2 years.SELECTED DRAWING: None
Owner:GENNOVA BIOPHARMACEUTICALS LTD

Cancer treatment using a combination of CD47 inhibitors, immune checkpoint inhibitors, and standard therapies.

To provide effective cancer treatments. [Solution] The present invention provides a cancer treatment method that combines a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody), and standard therapy (e.g., combination therapy of FOLFOX therapy with bevacizumab or cetuximab for unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a reduced-dose regimen for pancreatic cancer with distant metastases).
Owner:ONO PHARMA CO LTD

Use of bevacizumab in the preparation of a medicament for inhibiting hemorrhagic lesions of cerebral vascular malformations

The application provides application of bevacizumab in preparation of a medicine for inhibiting hemorrhagic lesions of cerebral vascular malformations, and belongs to the technical field of medicine application. The application firstly discovers and proves by experiments that bevacizumab can be used for binding free VEGF molecules in serum of a patient with a cavernous cerebral vascular malformation, thereby inhibiting a VEGF path, and having obvious inhibiting effect on symptomatic hemorrhagic lesions of the cavernous cerebral vascular malformation, and developing a new use of bevacizumab, and providing a new selection of drug treatment for the patient with the cavernous cerebral vascular malformation.
Owner:BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Methods for treatment of liver cancer

The present invention relates to the treatment of liver cancer, e.g., hepatocellular carcinoma (HCC), e.g., resectable HCC. More specifically, the invention pertains to the treatment of patients having an HCC by administering (i) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab); (ii) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab), a VEGF antagonist (e.g., bevacizumab), and an anti-TIGIT antagonist antibody (e.g., tiragolumab); or (iii) a combination of a bispecific antibody that binds to PD-1 and LAGS (e.g., tobemstomig) and a VEGF antagonist (e.g., bevacizumab).
Owner:GENENTECH INC

Methods for treatment of liver cancer

The present invention relates to the treatment of liver cancer, e.g., hepatocellular carcinoma (HCC), e.g., resectable HCC. More specifically, the invention pertains to the treatment of patients having an HCC by administering (i) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab); (ii) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab), a VEGF antagonist (e.g., bevacizumab), and an anti-TIGIT antagonist antibody (e.g., tiragolumab); or (iii) a combination of a bispecific antibody that binds to PD-1 and LAG3 (e.g., tobemstomig) and a VEGF antagonist (e.g., bevacizumab).
Owner:GENENTECH INC

Drug-loaded microgel-gel sustained-release dressing as well as preparation and application thereof

The invention discloses a drug-loaded microgel-gel sustained-release dressing as well as a preparation method and application of the drug-loaded microgel-gel sustained-release dressing. The dressing comprises a drug microgel phase loaded by GelMA microspheres and a hydrogel shell phase formed by copolymerizing CSMA and a double-bond-containing micromolecule cross-linking agent, and can be polymerized and cured in situ through ultraviolet light. The carried medicine comprises one of bevacizumab, triamcinolone acetonide and fluorouracil, and multi-medicine synergistic slow release is achieved. The dressing provided by the invention has good biocompatibility, degradability, shape adaptability and slow release performance, can significantly improve local drug concentration, reduce administration frequency and improve patient compliance, and is suitable for treatment and repair of keloid.
Owner:QILU HOSPITAL(QINGDAO) CHEELOO COLLEGE OF MEDICINE SHANDONG UNIV